Skip to content

Based on my review of the GO-CAM model gomodel:6606056e00002011 titled "CD72 and BCR co-stimulation by sn/RNP self antigen (Human)" and the relevant documentation and literature, I will now provide a comprehensive assessment of this model.

GO-CAM Review: gomodel:6606056e00002011

Model Overview

This model (gomodel:6606056e00002011) represents the interactions between CD72 and the B cell receptor (BCR) complex during co-stimulation with the sn/RNP self antigen in human cells. The model includes four key activities:

  1. B cell receptor (BCR) complex (CD79A/CD79B) transmembrane signaling receptor activity
  2. LYN protein tyrosine kinase activity
  3. CD72 transmembrane signaling receptor activity
  4. PTPN6/SHP-1 protein tyrosine phosphatase activity

Model Strengths

  1. Appropriate representation of the BCR complex: The model correctly represents the BCR complex as a protein complex consisting of CD79A and CD79B. According to the "How to annotate complexes in GO-CAM" guide, when multiple proteins form a complex with shared activity, using a complex representation is appropriate.

  2. Correct signaling pathway relationships: The model properly uses causal relationships (RO:0002629 "directly positively regulates") to connect the activities in the signaling pathway, following the chain from BCR to LYN to CD72 to PTPN6.

  3. Correct cellular localization: All activities are properly annotated with their cellular locations - the receptor activities occurring at the plasma membrane (GO:0005886) and PTPN6 in the cytoplasm (GO:0005737).

  4. Appropriate biological processes: Each activity is correctly associated with relevant biological processes - BCR complex with BCR signaling pathway (GO:0050853), LYN with B cell homeostasis (GO:0001782), CD72 with negative regulation of BCR signaling (GO:0050859), and PTPN6 also with negative regulation of BCR signaling.

  5. Evidence support: The model includes appropriate evidence codes and references for the assertions, primarily using experimental evidence from relevant publications.

Areas for Improvement/Considerations

  1. Self-antigen representation: The model does not explicitly show how the sn/RNP self-antigen initiates the signaling pathway. According to the "Signaling receptor activity annotation guidelines", there are specific ways to represent how ligands interact with receptors. Although sn/RNP is not a protein ligand (it's a nucleoprotein complex), it would be helpful to include it in the model to show the complete picture of how CD72 and BCR are co-stimulated.

  2. Pathway completeness: The molecular functions between LYN kinase activity and CD72 receptor activity could be more explicitly detailed. The model shows LYN directly regulating CD72, but it would be valuable to include any intermediate steps if they are known.

  3. Evidence consistency: While the model does include evidence codes and references, some activities use sequence similarity evidence (ECO:0000250) with references to mouse (MGI) rather than direct experimental evidence in humans. Where possible, human-specific experimental evidence would strengthen the model.

  4. Additional downstream effects: If known, it would be beneficial to include additional downstream effects of PTPN6/SHP-1 phosphatase activity, particularly how it ultimately impacts B cell function or fate.

Scientific Accuracy Assessment

Based on my review of the literature provided and the model content:

  1. BCR Complex: The model correctly represents the BCR complex as consisting of membrane immunoglobulin associated with CD79A/CD79B heterodimers, which is consistent with current understanding of BCR structure.

  2. CD72 function: The model accurately depicts CD72 as a negative regulator of BCR signaling, which aligns with the literature showing that CD72 negatively regulates B cell responses to sn/RNP via recruitment of SHP-1/PTPN6.

  3. LYN kinase role: The model appropriately places LYN kinase as an early component of BCR signaling, which is supported by the literature describing LYN as one of the first kinases activated following BCR engagement.

  4. Negative regulation pathway: The pathway from CD72 to PTPN6/SHP-1 is accurate, as the literature confirms that CD72 recruits the phosphatase SHP-1 to negatively regulate BCR signaling.

  5. Spatial organization: The cellular locations of the activities are scientifically accurate, with receptors at the plasma membrane and downstream signaling components in the cytoplasm.

Comparison to GO-CAM Best Practices

The model generally follows GO-CAM best practices:

  1. Complex representation: The model correctly uses a protein complex association to represent the BCR complex, following the guidelines in the "How to annotate complexes in GO-CAM" document.

  2. Signaling relationships: The causal relationships between activities follow the guidelines for representing signaling pathways, using "directly positively regulates" (RO:0002629) appropriately.

  3. Contextual annotations: Each activity has appropriate contextual annotations (cellular component and biological process), following GO-CAM standards.

  4. Evidence codes: The model uses appropriate evidence codes, although more direct experimental evidence rather than sequence similarity would be preferred where available.

Conclusion

Overall, this GO-CAM model (gomodel:6606056e00002011) provides a scientifically accurate representation of CD72 and BCR co-stimulation by sn/RNP self-antigen in humans. The model follows GO-CAM best practices for representing complexes and signaling pathways, with appropriate contextual annotations and evidence.

The model could be enhanced by explicitly representing the sn/RNP self-antigen and its interaction with both CD72 and the BCR, as well as by including additional downstream effects of PTPN6/SHP-1 activity if known. Additionally, using human-specific experimental evidence rather than evidence inferred from mouse would strengthen the model where possible.

In summary, this is a well-constructed GO-CAM model that accurately represents key aspects of the CD72 and BCR co-stimulation pathway and its negative regulation in human B cells.